Deutsche Bank analyst Amit Mehrotra believes any health-related developments relating to Hunter Harrison are critical for CSX given the CEO's status as a change-agent for the company. The analyst, however, feels concerns following last night's Wall Street Journal are likely overstated. The report's mention of Harrison's limited sightings at CSX headquarters is "largely irrelevant," Mehrotra tells investors in a research note. Further, the analyst says use of an "over-the-shoulder oxygen system" is not nearly enough information to draw any conclusions. Mehrotra has a Buy rating on CSX shares.